| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000418064 |
| ISSN: | 1665-2681 |
| Autores: | Urquijo, Juan José1 Diago, Moisés1 Boadas, Jaume2 Planas, Ramón3 Solá, Ricard4 Olmo, Juan Angel del5 Crespo, Javier6 Erdozaín, José Carlos7 Antón, María Dolores8 Arocena, Carlos9 Suárez, Dolores10 Giné, Jose11 Barrera, Josep M12 García Samaniego, Javier13 Pérez, Ricardo14 Dalmau, Blai15 Montoro, Miguel16 |
| Instituciones: | 1Consorcio Hospital General Universitario, Valencia. España 2Hospital de Terrassa, Barcelona. España 3Hospital Germans Trias i Pujol, Badalona, Barcelona. España 4Hospital del Mar, Barcelona. España 5Hospital Clínico de Valencia, Valencia. España 6Hospital Valdecilla, Santander. España 7Hospital La Paz, Madrid. España 8Hospital Dr. Peset, Valencia. España 9Fundación Jimenez Diaz, Madrid. España 10Hospital Arquitecto Marcide, Ferrol. España 11Hospital Verge de la Cinta, Tortosa, Tarragona. España 12Hospital Clinic de Barcelona, Barcelona. España 13Hospital Carlos III, Madrid. España 14Hospital General Universitario, Albacete. España 15Hospital Parc Tauli Sabadell, Sabadell. España 16Hospital San Jorge Huesca, Huesca. España |
| Año: | 2013 |
| Periodo: | Feb |
| Volumen: | 12 |
| Paginación: | 30-35 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental |
| Resumen en inglés | The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have focused on genotype 4 patients, who have had a poor representation in pivotal trials. Our aim was to evaluate the efficacy and safety of treatment with standard dose pegylated interferon alfa-2a in combination with weight-based ribavirin in patients with chronic hepatitis C genotype 4. In this prospective observational study, 198 patients with HCV-4 were included in this study from February 2004 to August 2005,188 patients who received at least 1 dose of drugs were included in the ITT analysis and they were treated with pegylated interferon alfa-2a and ribavirin for 48 weeks. Baseline and demographic characteristics, response to treatment at weeks 12, 48 and 72, and the nature and frequency of adverse effects were analyzed. Virological response at week 12 was achieved in 144 patients (76.6%). Virological response at the end of treatment was present in 110 patients (58.5%). At week 72, 99 patients presented SVR (52.7%). The reported adverse events were similar to those found in the literature for treatments of similar dose and duration. In conclusion, combined treatment with pegylated interferon alfa-2a and ribavirin was well tolerated and effective in chronic hepatitis C genotype 4, yielding response rates between those reported for genotype 1 and those of genotypes 2-3 |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Farmacología, Peginterferón, Ribavirina, Respuesta sostenida, Virus de la hepatitis C, Genotipos |
| Keyword: | Gastroenterology, Pharmacology, Peginterferon, Ribavirin, Sustained response, Hepatitis C virus, Genotypes |
| Texto completo: | Texto completo (Ver PDF) |
